About Us - Overview
Glenmark Pharmaceuticals Limited is a research‐led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus in the therapy areas of Respiratory, Dermatology and Oncology. The company has four research and development centres, ten world‐class manufacturing facilities spread across five continents, and operations in over eighty countries.
In its quest to be among the first few Indian pharmaceutical companies to develop an innovative drug for the world, Glenmark is treading two parallel paths. One pursues the discovery of a novel chemical or biological entity. The second that leads towards scaling the value chain by creating specialty products, like RYALTRIS®, that address gaps in treatment.
Glenmark Pharmaceuticals and its fully owned US subsidiary Ichnos Sciences together have formed an alliance ‘Ichnos Glenmark Innovation’ to use different modalities, technologies and combined expertise to treat cancer. It has a robust pipeline of innovative molecules, in various stages of clinical development across oncology and immunology.
Glenmark is driven by a continuous commitment to create ‘A New Way for a New World’. Harnessing the potential of our core strengths of innovation, research, and scientific knowledge, we remain determined to consistently challenge established treatment paradigms. It allows us to identify and deliver promising solutions that make a considerable difference to the lives of patients in diverse geographies.
Our Vision and Values
To emerge as a leading, research-led, global pharmaceutical company.
ACHIEVEMENT
We value the achievement of objectives and consistently strive towards our vision, with perseverance
KNOWLEDGE
We place an importance on knowledge such that it empowers our people to find innovative solutions to manage change.
RESPECT
We respect all our stakeholders.
Fact File
83
Ranks amongst the World’s Top 100 Biopharmaceuticals companies and 50 Generics and Biosimilars Companies*
50
15
Employees worldwide, including 1400+ in R&D
+
10
Manufacturing facilities
04
4 state-of-the-art R&D centres spanning across Glenmark Pharmaceuticals Limited and Ichnos Glenmark Innovation
80
Commercial presences in over 80 countries, with more than 60% revenue coming from international markets
*(Top 100 Companies Ranked by Pharmaceutical R&D and Sales, 2022,
by In Vivo/Scrip 100 and Top 50 Generics and Biosimilars Companies ranked by Sales, 2022, by Generics Bulletin/In Vivo).
